Clinical trials for inflammatory bowel disease: a global guidance during COVID-19 pandemic

Walter Reinisch¹, Silvio Danese², Laurent Peyrin-Biroulet³, Edward V. Loftus, Jr.,⁴ on behalf of the International Organization for the Study of Inflammatory Bowel Diseases (IOIBD)

Walter Reinisch 1, MD; walter.reinisch@meduniwien.ac.at
Department of Internal Medicine III, Division Gastroenterology & Hepatology, Medical University of Vienna, Vienna, Austria

Silvio Danese 2, MD; silvio.danese@humanitas.it
Inflammatory Bowel Disease Center, Humanitas University, IRCCS Humanitas Research Hospital, Milano, Italy

Laurent Peyrin-Biroulet 3, MD; peyrinbiroulet@gmail.com
Inserm NGERE U1256 and Department of Gastroenterology, Nancy University Hospital, Lorraine University, France

Edward V. Loftus, Jr. 4, MD; loftus.edward@mayo.edu
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, U.S.A.

Corresponding Author

Walter Reinisch, MD
Medical University of Vienna, Dept. Internal Medicine III, Div. Gastroenterology & Hepatology, Währinger Gürtel 18-20, 1090 Vienna,

Austria

© The Author(s) 2020. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissions@oup.com
Author Contributions: W.R. generated the idea of the manuscript and wrote the first draft of the manuscript. SD, LPB, and EVL critically reviewed and modified the draft in an iterative fashion.

Acknowledgements: All authors are members of the International Organization for the Study of Inflammatory Bowel Diseases (IOIBD)

Conflicts of interest:

WR has served as a speaker for Abbott Laboratories, Abbvie, Aesca, Aptalis, Astellas, Centocor, Celltrion, Danone Austria, Elan, Falk Pharma GmbH, Ferring, Immundiagnostik, Mitsubishi Tanabe Pharma Corporation, MSD, Otsuka, PDL, Pharmacosmos, PLS Education, Schering-Plough, Shire, Takeda, Therakos, Vifor, Yakult; as a consultant for Abbott Laboratories, Abbvie, Aesca, Algernon, Amgen, AM Pharma, AMT, AOP Orphan, Arena Pharmaceuticals, Astellas, Astra Zeneca, Avaxia, Roland Berger GmbH, Bioclinica, Biogen IDEC, Boehringer-Ingelheim, Bristol-Myers Squibb, Cellerix, Chemocentryx, Celgene, Centocor, Celltrion, Covance, Danone Austria, DSM, Elan, Eli Lilly, Ernest & Young, Falk Pharma GmbH, Ferring, Galapagos, Genentech, Gilead, Grünenthal, ICON, Index Pharma, Inova, Intrinsic Imaging, Janssen, Johnson & Johnson, Kyowa Hakko Kirin Pharma, Lipid Therapeutics, LivaNova, Mallinckrodt, Medahead, MedImmune, Millenium, Mitsubishi Tanabe Pharma Corporation, MSD, Nash Pharmaceuticals, Nestle, Nippon Kayaku, Novartis, Ocera, OMass, Otsuka, Parexel, PDL, Periconsulting, Pharmacosmos, Philip Morris Institute, Pfizer, Procter & Gamble, Prometheus, Protagonist, Provention, Robarts Clinical Trial, Sandoz, Schering-Plough, Second Genome, Seres Therapeutics, Setpointmedical, Sigmoid,
Sublimity, Takeda, Therakos, Theravance, Tigenix, UCB, Vifor, Zealand, Zyngenia, and 4SC; as an advisory board member for Abbott Laboratories, Abbvie, Aesca, Amgen, AM Pharma, Astellas, Astra Zeneca, Avaxia, Biogen IDEC, Boehringer-Ingelheim, Bristol-Myers Squibb, Cellrix, Chemocentryx, Celgene, Centocor, Celltrion, Danone Austria, DSM, Elan, Ferring, Galapagos, Genentech, Grünewald, Inova, Janssen, Johnson & Johnson, Kyowa Hakko Kirin Pharma, Lipid Therapeutics, MedImmune, Millenium, Mitsubishi Tanabe Pharma Corporation, MSD, Nestle, Novartis, Ocera, Otsuka, PDL, Pharmacosmos, Pfizer, Procter & Gamble, Prometheus, Sandoz, Schering-Plough, Second Genome, Setpoint Medical, Takeda, Therakos, Tigenix, UCB, Zealand, Zyngenia, and 4SC.

SD reports consultancy fees from AbbVie, Allergan, Amgen, AstraZeneca, Athos Therapeutics, Biogen, Boehringer Ingelheim, Celgene, Celltrion, Ely Lilly, Enthera, Ferring Pharmaceuticals Inc., Gilead, Hospira, Inotrem, Janssen, Johnson & Johnson, MSD, Mundipharma, Mylan, Pfizer, Roche, Sandoz, Sublimity Therapeutics, Takeda, TiGenix, UCB Inc., and Vifor

LPB has received personal fees from AbbVie, Janssen, Genentech, Ferring, Tillots, Pharmacosmos, Celltrion, Takeda, Boehringer Ingelheim, Pfizer, Index Pharmaceuticals, Sandoz, Celgene, Biogen, Samsung Bioepis, Alma, Sterna, Nestle, Enterome, Allergan, MSD, Roche, Arena, Gilead, Hikma, Amgen, BMS, Vifor, Norgine; Mylan, Lilly, Fresenius Kabi, Oppilan Pharma, Sublimity Therapeutics, Applied Molecular Transport, OSE Immunotherapeutics, Enthera, Theravance; grants from Abbvie, MSD, Takeda

EVL has consulted for AbbVie, Allergan, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Celltrion Healthcare, Genentech, Gilead, Eli Lilly, Janssen, Pfizer, Takeda, and UCB Biopharma; and has received research support from AbbVie, Bristol-Myers Squibb, Celgene, Genentech, Gilead, Janssen, Pfizer, Robarts Clinical Trials, Takeda, and UCB Biopharma.
Abstract

The severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]-causing coronavirus disease [COVID]-19 pandemic poses major challenges for patients with inflammatory bowel disease to be recruited and maintained in clinical trials. However, clinical trials offer patients who have failed multiple drugs access to study medications with alternative mode of action and the potential for relief from inflammation-mediated symptoms. Therefore, the continuation of clinical trials in IBD during the COVID-19 pandemic is important both for participants and the community of IBD patients, due to the dire need of an expanded therapeutic armamentarium. As the safety of patients in clinical trials is the leading principle, we are providing ten specific rules to guide patients and principal investigators safely through the challenging time.
Introduction

Over recent years, the inflammatory bowel diseases (IBD), ulcerative colitis (UC) and Crohn’s disease (CD), have attracted major interest by pharmaceutical companies as indications for new drug development. A survey from 2019 (i.e., the year before the outbreak of the severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]-related coronavirus disease [COVID]-19 pandemic revealed 47 companies recruiting up to 50,000 patients into phase II and III clinical trials on IBD for a total of 68 new investigational drugs. Impressively, despite rising numbers of approved biologics and small molecules these figures also represent the unmet demand for novel medical therapies in IBD. As such, clinical trials provide physicians and patients with IBD access to new drugs with alternative modes of action, increasingly for patients who previously have failed multiple medical interventions.

The COVID-19 crisis has numerous implications for the care of patients with IBD resulting in shifting priorities for treating sites and patients as outlined in detail elsewhere. From the availability of general protective measures to IBD-specific opinion-based management recommendations, guidance documents have been published to help safely steer physicians and patients through this time of exceptionally infectious circumstances. However, there are also several challenges eroding the initiation and continuation of clinical trials in IBD. Travel limitations, quarantine separations, site/region/country-specific public health measures with resulting consequences including dropping of non-urgent procedures such as endoscopy for endpoint assessment, interruption to the supply chain, and patients’ reluctance including concerns about a potentially increased infection risk from the study medication, might jeopardize the integrity of a clinical trial.

The Food and Drug Administration (FDA), the European Medicines Agency (EMA) and other regulatory authorities have issued regularly up-dated general guidance documents for industry, investigators, and institutional review boards (IRB) to assist in assuring the safety of trial participants, maintaining compliance with good clinical practice (GCP) and minimizing risks to trial integrity during the COVID-19 pandemic. In contrast, literature addressing the very specifics on the conduct of clinical trials in IBD during COVID-19 is sparse and mostly limited to considerations generated by the COVID-19 IBD working group of the British Society of Gastroenterology (BSG). The International Organization for the Study of
Inflammatory Bowel Disease (IOIBD), an international, global organization to promote the health of people with IBD, has established numerous task forces to address the various aspects of management of IBD during the COVID-19 pandemic. Here, we report guidance for investigators of clinical trials on patients with IBD.

**General Considerations regarding Clinical Trials in IBD during COVID-19 pandemic**

The feasibility of screening and recruiting new trial participants in an ongoing study and continuing enrolled participants should be carefully assessed, individually, at each study site, in collaboration with the sponsor and IRB. Additional considerations include country or regional regulatory measures, maintenance of supply chain for study drug and samples, time, and site’s clinical resources and safety. As an overarching principle, protecting the safety of trial participants and study staff is of paramount importance. The specific guidance from the other IOIBD COVID-19 task forces on risk mitigation measures in terms of acute care, infusion centres, endoscopy, and telehealth also funnel into the safe conduct of clinical trials in IBD. Without repetition we encourage the detailed study of those publications elsewhere in this issue of the Journal of Crohn’s and Colitis.

Whereas recruitment hold for new participants has been issued by sponsors and new site activation has been suspended until further notice for most studies in IBD, some studies still permit enrollment of new patients if conditions allow.

Patients lacking therapeutic alternatives (e.g., patients who are steroid-dependent despite multiple biologics and small molecules, patients with a history of serious adverse events such as severe infections or paradoxical inflammation in association with approved mode of actions, or patients who lack access to approved drugs) might still be candidates for enrolment into clinical trials. However, the decision to recruit a new patients in a trial mandates balancing of the potential benefits of receiving trial medication against the risk of trial participation including travel to the study site, face-to-face visits, and the unknown effects of the investigational medicinal product (IMP) on the course of COVID-19, as also suggested by the BSG. Preventing increased disease activity, continuous/repetitive use of corticosteroids and unanticipated (emergent) surgeries are a leading principles in the
treatment of IBD patients that continues to apply during the coronavirus pandemic. The increased risk of serious and opportunistic infections in patients with CD with higher disease activity and with concomitant use of corticosteroids is noteworthy in that context and could be determining factors for the recruitment decision in patients lacking approved therapeutic alternatives.\textsuperscript{vii} It is important to note that high doses of corticosteroids have been associated with delayed viral clearance during previous coronavirus outbreaks in MERS and SARS and interim guidance from the World Health Organization (WHO) advised against the use of steroids for SARS-CoV2-induced lung injury.\textsuperscript{viii, ix} Furthermore, endocrinologists issued warnings that individuals taking steroid hormones are at higher risk to acquire SARS-CoV2 infection and if infected, might be prone to a more severe course.\textsuperscript{x} Early results from the SECURE-IBD registry, recruiting IBD patients with proven COVID-19, support an increased risk of severe COVID-19, defined as composite of intensive care unit admission, ventilator use, and/or death, in association with concomitant use of glucocorticoids.\textsuperscript{xii} In an exploratory analysis, combination therapy of TNF antagonist with thiopurines or methotrexate compared to TNF antagonist monotherapy was positively associated with COVID-19-related hospitalization or death, suggesting against double immunosuppression treatment strategies during the time of pandemic if avoidable.

Most single target mode of actions, including blockade of interleukin(IL)-23 and anti-adhesion strategies, currently subjected to clinical phase III trials in IBD, appear to be involved in viral clearance of SARS-CoV-2.\textsuperscript{vi, xii} The jury is still out on Janus kinase (JAK) inhibitors, which target JAK1 and JAK3, as those affect multiple cytokines such as type I interferons, IL-2, IL-15, IL-21 and interferon-γ involved in antiviral responses. Sphingosine-1-phosphate receptor 1 modulators have been reported to protect from death in animal models caused by severe influenza infection. Whether those results could be extrapolated to patients with SARS-CoV-2 remains to be determined.\textsuperscript{xiii}

For recruited participants in ongoing IBD trials, COVID-19 illness and/or COVID-19 mitigation measures can negatively affect compliance with protocol-specified study procedures and schedules, including IMP administration, adherence to protocol specified visits and endpoint evaluations such as endoscopy for outcome assessment. Therefore, protocol modifications and deviations are expected and recognized by regulatory agencies and IRBs. In addition to assuring the integrity of patient data, sponsors need to evaluate the potential impact on
safety, not only study participants, but also study staff. Partnering and communications between investigators (and their IRBs), clinical research organizations (CROs), and industry sponsors should determine how to best approach challenges and develop solutions. Due to the acuteness of the situation, alternative study processes intended to immediately mitigate the risk from COVID-19 pandemic may be implemented prior to approval by IRB/regulatory authorities, which may not meet regularly due to the crisis and must be notified afterwards. The FDA and EMA require that these changes must be clearly and reproducibly documented in the clinical study report (e.g., home administration of IMP, local laboratory utilization, missing and remote visits, alternative treatment failure assessment in case endoscopy not available, transient or permanent discontinuation of treatment), by also providing details on duration of these changes and which trial subjects have been impacted to exactly what extent.

In general, the continuation of clinical trials for patients with moderate or severe IBD may be critical, in particular for those showing a clear clinical benefit regarding patient reported outcomes (PROs) that are corroborated by improvement of objective signs of inflammation, such as endoscopic disease activity and/or inflammatory biomarkers [faecal calprotectin (FCP) and serum C-reactive protein (CRP)]. Discontinuing patients with objective evidence of improvement, even in the absence of completed end-point assessments, can potentially compromise their overall well-being by exposure to recurrent inflammation and the associated risk of a flare necessitating “rescue” corticosteroids. As outlined above, both enhanced disease activity and corticosteroids should be avoided whenever possible. Furthermore, in several countries, patients have no other access to advanced targeted therapies, including biologics, leaving them insufficient treatment options after trial discontinuation.

Maintaining the scientific integrity of a clinical trial, in particular of phase III studies, is critical as it protects the contributions that have been made by the patients to date, but also as provision to achieve the pre-defined statistical objectives. The COVID 19 situation may introduce a number of significant events that may have potential impact on evaluation and power of study objectives from missing or alternative assessments, e.g. by replacing endoscopic endpoints with patient-reported outcomes (PROs) supported by biomarkers (CRP, FC). In order to minimize that risk, efforts by study staff based on benefit-risk
Considerations are warranted to adhere to protocol-mandated study procedures scheduled for endpoint visits, while taking into account local guidance. Delay in endoscopy assessments especially when it is the primary end-point can be negotiated to complement secondary end point criteria that may be available.

Regulatory agencies encourage conversion of physical visits into phone or video visits, utilization of alternative locations for assessments including local laboratory and imaging centres, home delivery and administration of IMP, and even postponement or complete cancellation of visits if the situation is too challenging and does not ensure safety. Each visit should be assessed on a case by case with tailored solutions. The COVID-19 restrictions are posing prime opportunity for the evolution to telemedicine modalities and the FDA is providing specific guidance on remote monitoring during the crisis. In exceptional situations, the transfer of participants to other investigational sites, either already participating or new ones, performing under safer conditions, could occur, particularly if the trial participant urgently needs to stay in the trial.

**Ten Specific rules regarding Clinical Trials in IBD during COVID-19 pandemic**

Figure 1 summarizes specific rules for the various stages of a clinical trial in patients with IBD.

1) Consider continuing recruited participants in ongoing trials if subject safety, site activity, supply chain, travel limitations and national/regional/local COVID-19 related restrictions allow. Particular attention should be paid to patients who lack therapeutic alternatives to approved drugs and who objectively benefit from the study.

2) Consider completing recruitment of screened patients who lack therapeutic alternatives and who have already undergone invasive procedure and meet eligibility.

3) Patients who are suspected for COVID-19 or have tested positive for SARS-CoV-2 should not be enrolled or initiated protocol treatment until resolution of symptoms or negative re-testing dependent upon the provision of sponsors. For ongoing patients who are exhibiting symptoms consistent with COVID-19, consider holding dosing of IMP and consult the
medical monitor. In the event a patient is tested positive for COVID-19 consistent with the institutional standard of care, or if no testing is available, immediately report to the sponsor and consider holding dosing until such time as symptoms resolve, before resuming to dose. COVID-19 may be mandatory before endoscopy at some sites. The outcome of potential COVID-19 cases should be tracked during the trial.

4) Try to keep the exposure to corticosteroids as low as possible with careful balancing of the advantages and disadvantages.

5) If possible, try to avoid or minimize duration of double immunosuppression during the conduct of the trial.

6) Consider unblinding of participants only if unavoidable such that disclosed information would determine further management, e.g. severe COVID-19 disease

7) Consider mitigation strategies (e.g. telemonitoring of PROs or adverse events, local laboratory for critical safety labs, home-based drug delivery, endoscopy at another site etc.) to keep participants in the trial if on site visits are exposing patients to an increase risk of coronavirus infections. Mitigations should also be considered if patients are not allowed to travel because of lockdown. Again, national/regional/local research guidance may help determine what is considered safe.

8) Consider a more expanded interpretation of timing of study visit windows, including endoscopy, dependent upon the pharmacology properties of the IMP (e.g. -2 to +4 weeks) in consultation with industry sponsors and CROs. These should be documented, before dropping visits or mandated procedures; in particular for endpoint assessment. However, criteria should be developed for patients to continue in the trial even without specified endoscopic examinations (e.g. by switching responders to open-label extensions if unable to attend end point procedures).

9) Ensure that all COVID-19 emergency related changes and/or modifications from the clinical study protocol (e.g. missed or late study visits, missed doses of study medication) are documented in the study file and notify IRB/ethics committee. Ensure a continuous bi-directional communication between sponsors, CROs and sites.
10) In case a sponsor holds or stops a clinical trial, investigators should resume standard therapy dependent upon disease severity in line with national and international scientific guidance.

Summary

We recognize that conducting a clinical trial in patients with IBD during the rapidly evolving situation elicited by COVID-19 with different geographical considerations poses numerous challenges regarding trial recruitment, retention and evaluations. Here we provide guidance in an attempt to maneuver patients safely through the crisis by maintaining the study’s scientific power and integrity. IBD affects patients not only by debilitating and embarrassing signs and symptoms, but also by social functioning and disability. As such, in addition to the development of novel therapies crucial to improve outcomes for these chronic inflammatory conditions, clinical trials also enable access to alternative modes of action in patients, with a progressive disease course who lack therapeutic alternatives. However, the safety of patients, investigators and staff involved in clinical trials is of paramount importance.
References

i Harris MS, Wichary J, Zadnik M, Reinisch W. Competition for Clinical Trials in Inflammatory Bowel Diseases. Gastroenterology. 2019 Dec;157(6):1457-1461.e2. doi: 10.1053/j.gastro.2019.08.020. Epub 2019 Aug 21. PubMed PMID: 31445038.

ii Danese S, Cecconi M, Spinelli A. Management of IBD during the COVID-19 outbreak: resetting clinical priorities. Nat Rev Gastroenterol Hepatol. 2020 Mar 25. doi: 10.1038/s41575-020-0294-8. [Epub ahead of print] PubMed PMID: 32214232.

iii Rubin DT, Feuerstein JD, Wang AY, Cohen RD. AGA Clinical Practice Update on Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: Expert
Commentary. Gastroenterology. 2020 Apr 10. pii: S0016-5085(20)30482-0. doi: 10.1053/j.gastro.2020.04.012. [Epub ahead of print] PubMed PMID: 32283100; PubMed Central PMCID: PMC7151253.

iv https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fda-guidance-conduct-clinical-trials-medical-products-during-covid-19-public-health-emergency

v https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-10/guidanceclinicaltrials_covid19_en.pdf

vi Kennedy NA, Jones GR, Lamb CA, Appleby R, Arnott I, Beattie RM, Bloom S, Brooks AJ, Cooney R, Dart RJ, Edwards C, Fraser A, Gaya DR, Ghosh S, Greveson K, Hansen R, Hart A, Hawthorne AB, Hayee B, Limdi JK, Murray CD, Parkes GC, Parkes M, Patel K, Pollok RC, Powell N, Probert CS, Raine T, Sebastian S, Selinger C, Smith PJ, Stansfield C, Younge L, Lindsay JO, Irving PM, Lees CW. British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic. Gut. 2020 Apr 17. pii: gutjnl-2020-321244. doi: 10.1136/gutjnl-2020-321244. [Epub ahead of print] PubMed PMID: 32303607.

vii Osterman MT, Sandborn WJ, Colombel JF, Peyrin-Biroulet L, Robinson AM, Zhou Q, Lewis JD. Crohn’s Disease Activity and Concomitant Immunosuppressants Affect the Risk of Serious and Opportunistic Infections in Patients Treated With Adalimumab. Am J Gastroenterol. 2016 Dec;111(12):1806-1815. doi: 10.1038/ajg.2016.433. Epub 2016 Sep 27. PubMed PMID: 27670599.

viii Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020 Feb 15;395(10223):473-475. doi: 10.1016/S0140-6736(20)30317-2. Epub 2020 Feb 7.
ix Neurath MF. Covid-19 and immunomodulation in IBD. Gut. 2020 Apr 17. pii: gutjnl-2020-321269. doi: 10.1136/gutjnl-2020-321269. [Epub ahead of print] Review. PubMed PMID: 32303609.

x Kaiser UB, Mirmira RG, Stewart PM. Our Response to COVID-19 as Endocrinologists and Diabetologists. J Clin Endocrinol Metab. 2020 May 1;105(5). pii: dgaa148. doi: 10.1210/clinem/dgaa148. PubMed PMID: 32232480; PubMed Central PMCID: PMC7108679.

xi Brenner EJ*, Ungaro RC*, Gearry RB, et al. Corticosteroids, but not TNF Antagonists, are Associated with Adverse COVID-19 Outcomes in Inflammatory Bowel Diseases: Results from an International Registry. Gastroenterology 2020 (accepted).

xii Schett G, Sticherling M, Neurath MF. COVID-19: risk for cytokine targeting in chronic inflammatory diseases? Nat Rev Immunol. 2020 May;20(5):271-272. doi: 10.1038/s41577-020-0312-7. PubMed PMID: 32296135.

xiii Teijaro JR, Walsh KB, Long JP, Tordoff KP, Stark GV, Eisfeld AJ, Kawaoka Y, Rosen H, Oldstone MB. Protection of ferrets from pulmonary injury due to H1N1 2009 influenza virus infection: immunopathology tractable by sphingosine-1-phosphate 1 receptor agonist therapy. Virology. 2014 Mar;452-453:152-7. doi: 10.1016/j.virol.2014.01.003. Epub 2014 Jan 31. PubMed PMID: 24606692; PubMed Central PMCID: PMC3954990.

xiv https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enforcement-policy-non-invasive-remote-monitoring-devices-used-support-patient-monitoring-during